IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.

Slides:



Advertisements
Similar presentations
SARQA/DKG Conference 3-4 October SARQA/DKG Conference 3-4 OCTOBER 2002 Annex 13 Update An Industry Perspective Michael J Cooke Director, Global.
Advertisements

Timelines Trust informed June 2007
Maintenance, Management and Monitoring of Investigational Supply
Tips to a Successful Monitoring Visit
Biopharmaceutical Quality
Special populations- What makes them so special? AGAH Association for Applied Human Pharmacology Annual meeting 2004 Berlin 29. Februar 2004 Birka Lehmann.
HOT TOPICS ARCHIVING OR HOW NOT TO DUMP YOUR RUBBISH!
IMP management at site Kathryn Bethune Clinical Trials Pharmacist
Audit of IT Systems SARQA / DKG Scandinavian Conference, October 2002, Copenhagen Sue Gregory.
The Global Health Network
Management of Medicines and Pharmaceutical Supplies for use in the prevention and treatment of Pre-eclampsia and Eclampsia Grace Adeya, SPS/MSH February.
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Model guidance for storage and transport of time and temperature-sensitive pharmaceutical products (WHO Technical Report Series, no.961, 2011, Annex 9)
Reference, Retention and Reserve Samples
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
Regulatory requirements on Medicine Stability Guidelines relevant for Stability testing Sultan Ghani.
Tool Summary Sheet Note: This hidden slide will not show in a slide presentation. Remove before providing slide deck to sites. Tool: Sponsor Responsibilities.
Investigational Pharmacy Issues Debbie Mundie, RPH Aka: The Drug “Nazi” “She should be in Law Enforcement” “She’s nice, but PICKY” McGuire VAMC Richmond.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Jennifer McCormick MA, CRC Karla Lichter RN CCRC.
Clinical Trials and Pharmacy
Coordinator University Clinical Research Pharmacy Investigational Drug Service (IDS) Marjorie Shaw Phillips, MS, RPh, FASHP Clinical Research Pharmacist.
World Health Organization
Monitoring and Special Considerations for Multi-Center Trials
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
By J.Thitiri KEMRI-Wellcome Trust Research Programme Kilifi, Kenya PHARMACY AND PRODUCT ACCOUNTABILITY Version: 14-Nov-2009.
A Basic Overview of the US FDA’s Regulations for Regulatory Compliance
Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
RESPONSIBILITIES OF INVESTIGATOR
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
Investigational New Drug Application (IND)
IMP management at site Dmitry Semenyuta. 2 TOP 5 FDA inspections finding Center of Drug Evaluation and Research (CDER) Failure to follow the.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Important informations
ANJALI JADHAV ANKITA SINGH ANUJA AHIRE ANURADHA PRASAD BEVIN D’SOUZA.
1 January 17, 2008 Test Article Accountability. 2 January 17, 2008 Investigator Responsibilities 21 CFR  Maintain control of drug under investigation.
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
Authorization Part III. Content of a license Structure of a license General elements General and specific conditions Annexes Documents attached (e.g.
IP Accountability in Outpatient Clinical Trials
Storage of Pharmaceutical Products Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
 Good Clinical Practice is a set of guidelines for biomedical studies which encompasses the design, conduct, termination, audit, analysis, reporting.
ICH guidelines……….. INVESTIGATOR INVESTIGATOR Investigator's Qualifications and agreements The investigator(s) should be qualified by education, training,
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
IP Accountability in Outpatient Clinical Trials Jessica Rinaldi, CCRP Farber Institute for Neurosciences.
BSB Biomanufacturing CHAPTER 4 GMP – Documentation Part I (SOP)
GOOD MANUFACTURING PRACTICE FOR BIOPROCESS ENGINEERING (ERT 425)
Responsibilities of Sponsor, Investigator and Monitor
Information on Medicinal Products
MAINTAINING THE INVESTIGATOR’S SITE FILE
Administering Informed Consent Issues for Discussion
PHARMACEUTICAL QUALITY
Pharmacovigilance in clinical trials
WHO Technical Report Series, No. 953, 2009
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Safety and Security of Radiation Sources
Regulatory Binder: Maintaining Essential Study Documentation
Quality Control SOP 3.12 Release Date: 08/10/2015.
MAINTAINING THE INVESTIGATOR’S STUDY FILE
Quality guidelines on impurities
Good clinical practice
Storage and distribution
Presentation transcript:

IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.

Sourcing of IMP/Placebo A sponsor responsibility Sourcing of product(s) of acceptable quality Blinding / production of placebo Labelling Quality and stability assessments Documentation

Sourcing of IMP/Placebo Quality Required amount of correct drug, within acceptable limits No harmful excipients Fit for the purpose of the trail Sufficient stability for duration of trial Documentation to prove this Acceptable to participants See EMEA CHMP: Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials (2006)

Sourcing of IMP/Placebo Quality

Sourcing of IMP/Placebo Blinding Over-encapsulation Manufacture of placebo Opaque covering for infusion / syringe Adverse effects may unblind the participants James Lind 20th of May 1747

Sourcing of IMP/Placebo Labelling EudraLex, Volume 4: EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use: Annex 13 Investigational Medicinal Products Labels should include: a) name of the sponsor; b) pharmaceutical dosage form, route of administration, quantity of dosage units (and name/identifier of the product and strength/potency in case of open trial); c) the batch and/or code number to identify the contents and packaging operation; d) the trial subject identification number, where applicable; e) directions for use; f) “for clinical trial use only”; g) the name of the investigator (if not included as a code in the trial reference code); h) a trial reference code allowing identification of the trial site and investigator; i) the storage conditions; j) the period of use (use-by date, expiry date or re-test date as applicable), in month/year); k) “keep out of reach of children

Sourcing of IMP/Placebo Documentation Application to the HPRA must include: Investigational Medicinal Product Dossier (IMPD)/ Simplified IMPD (incl. Section 2.1 Pharmaceutical information, Section 2.2 Pre- Clinical information, Section 2.3 Clinical Information) for all IMP and for placebo –a) Summary of Product Characteristics (SmPC) for products with marketing authorisation in the Community Investigator’s Brochure (IB) Examples of labelling

QP Release A statement by a Qualified Person confirming that the product has been manufactured to the standards which are appropriate for the product and the way the product is intended to be used. Required for all IMP. IMP sourced outside of the EU must also be released by an EU QP before it can be sent to investigational sites The first step of the procedure, ‘QP Certification’ ensures that the product has been manufactured in accordance with the requirements of EU Good Manufacturing Practice (GMP). The second step is the release of the IMPs by the Clinical Trial Sponsor, which confirms fulfilment of the requirements of Article 9 of the 9 of the EU directive 2001/20/EC (e.g. approval/favourable opinion from IRB/IEC and regulatory authority(ies))

Storage: In transit Transit storage is the responsibility of the trial sponsor Depending on stability of IMP, distance travelled, climatic conditions, may require transport in a temperature-controlled shipper, +/- inclusion of a data logger to demonstrate transit temperatures Responsibility of the investigator to follow sponsor procedures for assessment of transit conditions

Storage – at site Secure location – locked room or locked cabinet. Appropriate temperature: Ambient  C or  C » Refrigerated 2-8  C Protection from light may be needed Humidity may be an issue in some climates. Monitoring, to verify that IMP was stored appropriately at all times Report temperature excursions ASAP Alarm system See HPRA Guide to Control and Monitoring of Storage and Transportation Temperature Conditions for Medicinal Products and Active Substances. (2011 )

Storage – temperature mapping All rooms where trial drugs are stored are temperature mapped before IMP is stored in them. All fridges and freezers are temperature mapped before initial use. (full and empty) Temperature loggers are placed in expected hot and cold areas. (e.g windows,doors, near air conditioning units) Initially carried out summer and winter for three years.

Storage – temperature mapping

Storage: Fridges and freezers Fit for purpose Calibration prior to use Temp mapped Do not over fill IMP storage only Ongoing performance qualification Annual preventative maintenance and calibration.

Storage: temperature loggers Annual calibration Three point calibration over the range it’s being used at. Alarm logger and monitoring logger are separate.

Storage: temperature loggers

Reconciliation: ICH GCP The investigator/institution and/or a pharmacist or other appropriate individual, who is designated by the investigator/institution, should maintain records of the product's delivery to the trial site, the inventory at the site, the use by each subject, and the return to the sponsor or alternative disposition of unused product(s). These records should include dates, quantities, batch/serial numbers, expiration dates (if applicable), and the unique code numbers assigned to the investigational product(s) and trial subjects. Investigators should maintain records that document adequately that the subjects were provided the doses specified by the protocol and reconcile all investigational product(s) received from the sponsor.

Reconciliation: Accountability logs

Standard Operating Procedures

Some useful documents HPRA guide to clinical trial applications: v8 Aug 2014 European Communities (Clinical Trials on Medicinal Products for Human Use) Regulations, 2004, SI No 190 of 2004 and amendments Eudralex, Volume 10: Guidance Documents Applying to Clinical Trials, Questions and Answers EudraLex, Volume 4: EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use Annex 13 Investigational Medicinal Products IMB (HPRA) Guide to control and monitoring of storage and transportation temperature conditions for medicinal products and active substances (Oct 2011) EMEA CHMP: Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials (2006)